Here is the news to watch for November 18-24, 2024

Among the multitude of drugs in early development with data at AACR were: AbbVie’s ABBV-303, a TriNKET for solid tumors; Bayer and Vividion Thera-peutics’ 225Ac-PSMA-Trillium, a radioligand for metastatic cancer; Pfizer’s PF-07220060, a CDK4 inhibitor for breast cancer; Revolution Medicines’ RMC-9805, a KRASG12D inhibitor for solid tumors; and Vividion Therapeutics and Roche’s VVD-214/RO-7589831, a WRN helicase inhibitor for MSI-high cancers. Other research of interest at AACR: Hunter BioDiscovery’s high throughput plat-form for discovering new combinations of existing drugs. And some regulatory insights from the National Cancer Institute director.

Among the interesting data on new drugs (and new uses for existing drugs) at AAN were treatments for Angelman syndrome, chronic infectious demyelinating polyneuropathy (CIDP), Devic disease (NMOSD), Huntington's disease (HD), migraine, multiple sclerosis.

This is a must read for anyone interested in ODAC because changes are coming: In-person meetings will resume, less emphass on industry “outside experts,” a new style for briefing documents, encouragement for more “pragmatic” trials. Two things that won't change: panels will continue to vote, and drug prices will continue to be left out of discussions.

Drug development is alive and well in dermatology, and among the interesting data at AAD were studies on new drugs/new uses for existing drugs -- and a botanical -- for psoriasis, submental fat, hidradenitis suppurativa (HS), atopic dermatitis, and alopecia

2024 Medical Calendar - 2nd Half

Detecting minimal residual disease (MRD) in a breast cancer patient early sounds like a great idea. Here we look at the latest data on ctDNA testing -- the tests, physician opinions, and patient reactions.

The data on Eisai and Biogen’s Leqembi (lecanemab) was the highlight of the Clinical Trials on Alzheimer's Disease (CTAD) meeting in Boston. Here we dive into the data.